These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

385 related items for PubMed ID: 18759257

  • 21. Circulating concentration of infliximab and response to treatment in ankylosing spondylitis: results from a randomized control study.
    Krzysiek R, Breban M, Ravaud P, Prejean MV, Wijdenes J, Roy C, Henry YD, Barbey C, Trappe G, Dougados M, Emilie D, French Ankylosing Spondylitis Infliximab Network.
    Arthritis Rheum; 2009 May 15; 61(5):569-76. PubMed ID: 19405015
    [Abstract] [Full Text] [Related]

  • 22. Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data.
    Baraliakos X, Brandt J, Listing J, Haibel H, Sörensen H, Rudwaleit M, Sieper J, Braun J.
    Arthritis Rheum; 2005 Dec 15; 53(6):856-63. PubMed ID: 16342093
    [Abstract] [Full Text] [Related]

  • 23. Double blind, randomised, placebo controlled study of leflunomide in the treatment of active ankylosing spondylitis.
    van Denderen JC, van der Paardt M, Nurmohamed MT, de Ryck YM, Dijkmans BA, van der Horst-Bruinsma IE.
    Ann Rheum Dis; 2005 Dec 15; 64(12):1761-4. PubMed ID: 15901634
    [Abstract] [Full Text] [Related]

  • 24. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis.
    Calin A, Dijkmans BA, Emery P, Hakala M, Kalden J, Leirisalo-Repo M, Mola EM, Salvarani C, Sanmartí R, Sany J, Sibilia J, Sieper J, van der Linden S, Veys E, Appel AM, Fatenejad S.
    Ann Rheum Dis; 2004 Dec 15; 63(12):1594-600. PubMed ID: 15345498
    [Abstract] [Full Text] [Related]

  • 25. Infliximab treatment in ankylosing spondylitis: an observational study.
    Nikas SN, Alamanos Y, Voulgari PV, Pliakou XI, Papadopoulos CG, Drosos AA.
    Ann Rheum Dis; 2005 Jun 15; 64(6):940-2. PubMed ID: 15564309
    [Abstract] [Full Text] [Related]

  • 26. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study.
    Park W, Yoo DH, Jaworski J, Brzezicki J, Gnylorybov A, Kadinov V, Sariego IG, Abud-Mendoza C, Escalante WJ, Kang SW, Andersone D, Blanco F, Hong SS, Lee SH, Braun J.
    Arthritis Res Ther; 2016 Jan 20; 18():25. PubMed ID: 26795209
    [Abstract] [Full Text] [Related]

  • 27. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks.
    Davis JC, van der Heijde DM, Braun J, Dougados M, Cush J, Clegg D, Inman RD, Kivitz A, Zhou L, Solinger A, Tsuji W.
    Ann Rheum Dis; 2005 Nov 20; 64(11):1557-62. PubMed ID: 15843448
    [Abstract] [Full Text] [Related]

  • 28. Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab.
    Visvanathan S, Wagner C, Marini JC, Baker D, Gathany T, Han J, van der Heijde D, Braun J.
    Ann Rheum Dis; 2008 Apr 20; 67(4):511-7. PubMed ID: 17644552
    [Abstract] [Full Text] [Related]

  • 29. Treatment of refractory inflammatory monoarthritis in ankylosing spondylitis by intraarticular injection of infliximab.
    Schatteman L, Gyselbrecht L, De Clercq L, Mielants H.
    J Rheumatol; 2006 Jan 20; 33(1):82-5. PubMed ID: 16292792
    [Abstract] [Full Text] [Related]

  • 30. Infliximab in severe active ankylosing spondylitis with spinal ankylosis.
    Cheung PP, Tymms KE, Wilson BJ, Shadbolt B, Brook AS, Dorai Raj AK, Khoo KB.
    Intern Med J; 2008 Jun 20; 38(6):396-401. PubMed ID: 18336538
    [Abstract] [Full Text] [Related]

  • 31. Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study.
    Lambert RG, Salonen D, Rahman P, Inman RD, Wong RL, Einstein SG, Thomson GT, Beaulieu A, Choquette D, Maksymowych WP.
    Arthritis Rheum; 2007 Dec 20; 56(12):4005-14. PubMed ID: 18050198
    [Abstract] [Full Text] [Related]

  • 32. The cost-effectiveness of infliximab (Remicade) in the treatment of ankylosing spondylitis in Canada.
    Kobelt G, Andlin-Sobocki P, Maksymowych WP.
    J Rheumatol; 2006 Apr 20; 33(4):732-40. PubMed ID: 16583476
    [Abstract] [Full Text] [Related]

  • 33. Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial.
    Huang F, Gu J, Zhu P, Bao C, Xu J, Xu H, Wu H, Wang G, Shi Q, Andhivarothai N, Anderson J, Pangan AL.
    Ann Rheum Dis; 2014 Mar 20; 73(3):587-94. PubMed ID: 23475983
    [Abstract] [Full Text] [Related]

  • 34. Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial.
    Bao C, Huang F, Khan MA, Fei K, Wu Z, Han C, Hsia EC.
    Rheumatology (Oxford); 2014 Sep 20; 53(9):1654-63. PubMed ID: 24729398
    [Abstract] [Full Text] [Related]

  • 35. The cost-effectiveness of infliximab in the treatment of ankylosing spondylitis in Spain. Comparison of clinical trial and clinical practice data.
    Kobelt G, Sobocki P, Mulero J, Gratacos J, Collantes-Estevez E, Braun J.
    Scand J Rheumatol; 2008 Sep 20; 37(1):62-71. PubMed ID: 18189197
    [Abstract] [Full Text] [Related]

  • 36. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis.
    Ruperto N, Lovell DJ, Cuttica R, Wilkinson N, Woo P, Espada G, Wouters C, Silverman ED, Balogh Z, Henrickson M, Apaz MT, Baildam E, Fasth A, Gerloni V, Lahdenne P, Prieur AM, Ravelli A, Saurenmann RK, Gamir ML, Wulffraat N, Marodi L, Petty RE, Joos R, Zulian F, McCurdy D, Myones BL, Nagy K, Reuman P, Szer I, Travers S, Beutler A, Keenan G, Clark J, Visvanathan S, Fasanmade A, Raychaudhuri A, Mendelsohn A, Martini A, Giannini EH, Paediatric Rheumatology International Trials Organisation, Pediatric Rheumatology Collaborative Study Group.
    Arthritis Rheum; 2007 Sep 20; 56(9):3096-106. PubMed ID: 17763439
    [Abstract] [Full Text] [Related]

  • 37. Low-dose infliximab treatment for ankylosing spondylitis--clinically- and cost-effective.
    Jois RN, Leeder J, Gibb A, Gaffney K, Macgregor A, Somerville M, Scott DG.
    Rheumatology (Oxford); 2006 Dec 20; 45(12):1566-9. PubMed ID: 16705043
    [Abstract] [Full Text] [Related]

  • 38. Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial.
    Kavanaugh A, Krueger GG, Beutler A, Guzzo C, Zhou B, Dooley LT, Mease PJ, Gladman DD, de Vlam K, Geusens PP, Birbara C, Halter DG, Antoni C, IMPACT 2 Study Group.
    Ann Rheum Dis; 2007 Apr 20; 66(4):498-505. PubMed ID: 17114188
    [Abstract] [Full Text] [Related]

  • 39. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study.
    Deodhar A, Braun J, Inman RD, van der Heijde D, Zhou Y, Xu S, Han C, Hsu B.
    Ann Rheum Dis; 2015 Apr 20; 74(4):757-61. PubMed ID: 25387477
    [Abstract] [Full Text] [Related]

  • 40. Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis.
    Baraliakos X, Listing J, Rudwaleit M, Brandt J, Alten R, Burmester G, Gromnica-Ihle E, Haibel H, Schewe S, Schneider M, Sörensen H, Zeidler H, Visvanathan S, Sieper J, Braun J.
    J Rheumatol; 2007 Mar 20; 34(3):510-5. PubMed ID: 17299842
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.